Madsen, Sean D.
Russell, Katie C.
Tucker, H. Alan
Glowacki, Julie
Bunnell, Bruce A.
O’Connor, Kim C.
Funding for this research was provided by:
National Science Foundation (CBET-1066167)
National Institutes of Health (P51OD011104)
Tulane University (IDEA award)
National Science Foundation (CBET-1604129)
Article History
Received: 3 March 2017
Revised: 14 July 2017
Accepted: 22 August 2017
First Online: 29 September 2017
Ethics approval and consent to participate
: MSCs were obtained with written informed consent under a protocol reviewed and approved by the Tulane University (New Orleans, LA) Institutional Review Board (IRB protocol #160254-6). Additional bone marrow samples were obtained with Brigham and Women’s Hospital/Partners Institutional Review Board (Boston, MA) approval (IRB protocol #1999P001235) and annual review, as femoral tissue discarded during total hip replacement for non-inflammatory osteoarthritis. Criteria for exclusion were rheumatoid arthritis, cancer, and other comorbid conditions that could affect skeletal metabolism including renal insufficiency, alcoholism, active liver disease, malabsorption, hyperthyroidism, ankylosing spondylitis, aseptic necrosis, hyperparathyroidism, morbid obesity, and diabetes. Also excluded were patients who were taking medications that may influence skeletal metabolism (e.g., thyroid hormone, glucocorticoids, nonsteroidal anti-inflammatory drugs, and bisphosphonates).
: Not applicable
: KCO is the inventor listed on a patent application entitled “Cell-surface marker of early MSC aging” that has been filed on behalf of Tulane University and is under review in Australia, Canada, Europe, and the US. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.